Cycled Testosterone Replacement Study
The Effects of Cyclic Testosterone Administration on Muscle Function in Older Individuals
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas Medical Branch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Availability of transportation (i.e., subjects must be able to provide their own transportation to UTMB).
Exclusion Criteria:
- Medications such as anticoagulants (Coumadin) and glucocorticoids.
- History of angina that occurs with exertion or at rest.
- History of myocardial infarction within the last 12 months.
- Failure to successfully complete an exercise stress test using the Bruce protocol. Subjects that demonstrate ≥ 0.1 mV horizontal or downsloping ST segment depression, a drop in systolic blood pressure of ≥ 10 mm Hg, and/or frequent or repetitive arrhythmias (defined as ≥ 10 PVC/min, or couplets) during the stress test will be excluded.
- LDL cholesterol above 200 mg/dL.
- History of prostatic cancer.
- Elevated prostate specific antigen (PSA) above 4.0 µg/L, or severe benign prostatic hypertrophy (BPH) by history (frequent urination, reduced stream).
- Serum total testosterone concentrations of greater than 500 ng/dL.
- Subjects who engage in high intensity, elite training on a regular basis.
- Major medical illness such as diabetes, chronic obstructive pulmonary disease, or sleep apnea.
- Recent history of smoking tobacco.
- Hematocrit greater than 51%.
- Morbidly obese older men (BMI > 35).
- Hypertension: Blood pressure on three consecutive measurements taken at one week intervals that has a systolic pressure ≥ 140 or a diastolic blood pressure ≥ 90. Subjects will be included if they are on two or less blood pressure medications and have a blood pressure below these criteria.
- History of hepatitis or a 3-fold elevation of liver function tests (Alk phos, ALT, AST).
- Bone related disorders such as osteoporosis or parathyroid disease.
- DEXA scans revealing lumbar spine T-scores of less than -2.5.
- Subjects currently taking anti-bone-resorptive agents such as bisphosphonates, parathyroid hormone, or calcitonin.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo
Weekly placebo treatment for a duration of 5 months.
|
Weekly IM injections of sesame oil.
Other Names:
|
|
Experimental: Monthly Cycled Testosterone
A month of weekly testosterone treatment alternated by a month of weekly placebo treatment for a duration of 5 months.
|
Weekly IM injections of sesame oil.
Other Names:
Weekly im injections of 100 mg testosterone enanthate.
Other Names:
|
|
Experimental: Continuous Testosterone
Weekly testosterone treatment for a duration of 5 months
|
Weekly im injections of 100 mg testosterone enanthate.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Basal Muscle Protein Synthesis and Breakdown as Measured by Stable Isotope Metabolic Studies at Baseline and at Five Months
Time Frame: 5 Months
|
The fractional synthetic rate (FSR) of mixed muscle is calculated by directly measuring the incorporation of L-[ring-13C6]-phenylalanine into protein (%/hr),, using the precursor-product model: FSR = [(EP2 - EP1)/(EM•t)]•60•100, where EP1 and EP2 are the enrichments of bound L-[ring-13C6]-phenylalanine in the first and second muscle biopsies, t is the time interval (min) between biopsies, and EM is the mean L-[ring-13C6]-phenylalanine enrichment in the muscle intracellular pool.
|
5 Months
|
|
Changes in Muscle Strength as Measured by Maximal Voluntary Contraction Tests (Arm Curl) at Baseline, One Month, Two Months, Three Months, Four Months, and at Five Months
Time Frame: 5 months
|
Maximum weight (pounds) lifted using Cybex weight machine in a single effort(1-RM) for upper extremities (biceps and triceps) and lower extremities quadriceps and hamstrings).
|
5 months
|
|
Changes in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: 5 months
|
Lean body mass is expressed in grams as calculated by Hologic DEXA.
|
5 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Bone Mineral Density as Measured by Dual Energy X-ray Absorptiometry (DEXA)
Time Frame: 5 months
|
Bone mineral density measure by measured by dual energy x-ray absorptiometry (DEXA)measured at baseline and a five months
|
5 months
|
|
Changes in Serum Markers of Bone Turnover.
Time Frame: 5 months
|
Measures of bone turnover markers in serum samples at baseline and at five months.The bone turnover markers analyzed include: Markers associated with bone breakdown NTX (N-telopeptide) TRAP5b (tartrate-resistant acid phosphatase isoform 5b) Markers associated with bone formation Osteocalcin BAP (bone specific alkaline phosphatase) Regulators of bone formation iPTH (intact parathyroid hormone) increases in response to bone loss Calcitonin inhibits bone formation in response to elevated levels of serum calcium |
5 months
|
|
9473Changes in Serum Inflammatory Biomarkers and Muscle Inflammatory Cytokines
Time Frame: 5 months
|
Serum inflammatory biomarkers (Interleukin B-1, 2,5,6,7,8,10,12 13, Interferon gamma, GM-CSF, and Tumor Necrosis Factor alpha)as measured by immunoassay at baseline and at five months
|
5 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Randall J Urban, M.D., University of Texas
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Gonadal Disorders
- Hypogonadism
- Physiological Effects of Drugs
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Androgens
- Anabolic Agents
- Testosterone
- Methyltestosterone
- Testosterone undecanoate
- Testosterone enanthate
- Testosterone 17 beta-cypionate
Other Study ID Numbers
Other Study ID Numbers
- 01-302
- GCRC 615
- R01AG022023 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.